pharma · Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · BCAX
Bicara Therapeutics
Bicara Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2020
- Employees
- 115
- Programs
- 6
- Drugs
- 4
- Patents
- 0
Bicara Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Bicara Therapeutics.
Bicara Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BCA101X301
Bicara Therapeutics
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
1 trial -
Ficerafusp alfa
Bicara Therapeutics
Metastatic Head and Neck Squamous Cell Carcinoma
1 trial -
Ficerafusp alfa
Bicara Therapeutics
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
Ficerafusp alfa
Bicara Therapeutics
Squamous Cell Carcinoma of Head and Neck (SCCHN)
1 trial -
Pembrolizumab
Bicara Therapeutics
Head and Neck Squamous Cell Carcinoma
1 trial -
BCA101
Bicara Therapeutics
Head and Neck Squamous Cell Carcinoma
1 trial
Frequently asked questions
How many clinical projects does Bicara Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.